Global X Japan Co. Ltd. Boosts Stock Position in IDEXX Laboratories, Inc. $IDXX

Global X Japan Co. Ltd. boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 395.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,516 shares of the company’s stock after acquiring an additional 2,807 shares during the quarter. Global X Japan Co. Ltd.’s holdings in IDEXX Laboratories were worth $2,379,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its holdings in IDEXX Laboratories by 41.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock worth $1,313,992,000 after buying an additional 605,290 shares in the last quarter. Norges Bank acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at $221,955,000. JPMorgan Chase & Co. boosted its holdings in IDEXX Laboratories by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after purchasing an additional 326,348 shares during the period. Schroder Investment Management Group grew its stake in IDEXX Laboratories by 295.1% during the 2nd quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock worth $169,368,000 after purchasing an additional 235,863 shares in the last quarter. Finally, Zurich Insurance Group Ltd FI purchased a new stake in IDEXX Laboratories during the 3rd quarter worth about $143,730,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 1,464 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the sale, the director directly owned 648 shares of the company’s stock, valued at approximately $407,345.76. This trade represents a 69.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP George Fennell sold 11,345 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the completion of the transaction, the executive vice president owned 9,823 shares in the company, valued at $6,352,730.56. This trade represents a 53.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,957 shares of company stock valued at $29,862,109 in the last quarter. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Down 0.4%

IDXX opened at $573.29 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The business’s 50-day simple moving average is $634.46 and its 200-day simple moving average is $662.53. The stock has a market capitalization of $45.59 billion, a P/E ratio of 43.86, a price-to-earnings-growth ratio of 3.50 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.15. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the company earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on IDXX. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Barclays decreased their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. BTIG Research dropped their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Finally, Piper Sandler lowered their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Seven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $783.33.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.